Article information
El ovario es un órgano con capacidad germinal y endocrina, que sintetiza estrógenos, progesterona, andrógenos, factores locales de crecimiento, inhibinas, activina y folistatina.
En este artículo se revisa:
- 1.
La fisiología del eje hipófiso-gonadal y las diferentes técnicas de laboratorio utilizadas en la determinación de los parámetros informativos de la función germinal y endocrina, así como sus aplicaciones clínicas en entidades como la pubertad precoz y retrasada, los trastornos de la ovulación, el hiperandrogenismo ovárico y los trastornos gonadales secundarios a trastornos inmunológicos, radioterapia y quimioterapia.
- 2.
Las pruebas de estimulación y supresión utilizadas en el diagnóstico diferencial de los trastornos puberales y del hiperandrogenismo ovárico.
- 3.
La utilidad del cariotipo en la caracterización de los trastornos gonadales, específicamente el síndrome de Turner y el fallo ovárico precoz
Palabras clave:
Eje hipófiso-gonadal
Pruebas de estimulación ovárica
Pubertad precoz. Pubertad retardada
Hiperandrogenismo ovárico
Inhibina
Hormona antimülleriana
Síndrome de Turner
Fallo ovárico precoz
The ovary has both endocrine and reproductive functions and synthesizes estrogens, progesterone, androgens, growth factors, inhibins, activins and follistatin.
The present article reviews the following:
- 1.
The physiology of the pituitary-gonadal axis and the laboratory techniques used to assess both reproductive and endocrine functions, as well as their clinical application, specifically in precocious and delayed puberty, ovulatory dysfunction, ovarian hyperandrogenism, and gonadal abnormalities due to autoimmune diseases, chemotherapy and radiotherapy.
- 2.
The stimulation and suppression tests used in the differential diagnosis of pubertal disorders and ovarian hyperandrogenism.
- 3.
The usefulness of karyotype in the characterization of gonadal disorders, specifically Turner's syndrome and premature ovarian failure.
Key words:
Pituitary-gonadal axis
Ovarian stimulation tests
Precocious puberty
Delayed puberty
Ovarian hyperandrogenism
Inhibin
Antimüllerian hormone
Turner's syndrome
Premature ovarian failure
Full text is only aviable in PDF
Bibliografía
[1.]
L. Ibáñez, N. Potau.
Hiperandrogenismo.
Tratado de Endocrinología Pediátrica y de la Adolescencia, pp. 1043-1061
[2.]
N.P. Ibáñez.
Hiperandrogenismo: hirsutismo y ovario poliquístico.
Tratado de Endocrinología Pediátrica, 3.ª ed, pp. 880-896
[3.]
Ch. Bukowsky, M.A. Grigg, C. Longcope.
Sex Hormone-binding globulin concentration: differences among commercial available methods.
Clin Chem, 46 (2000), pp. 1415-1416
[4.]
K.E. Michelson, P.H. Petra.
A filter assay for the sex steroid binding protein (SBP) of human serum.
FEBS Lett, 44 (1974), pp. 31-38
[5.]
V. Jayagopal, E.S. Kilpatrick, P.E. Jennings, D.A. Hepburn, S.L. Atkin.
The biological variation of testosterone and sex hormone-binding globulin (SHBG) in polycystic ovarian syndrome: implications for SHBG as a surrogate marker of insulin resistance.
J Clin Endocrinol Metab, 88 (2003), pp. 1528-1533
[6.]
R.L. Rosenfield.
Hirsutism.
New Engl J Med, 353 (2005), pp. 2578-2588
[7.]
C. Wang, D.H. Catlin, L.M. Demers, B. Starcevic, R.S. Swerdloff.
Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry.
J Clin Endocrinol Metab, 89 (2004), pp. 534-543
[8.]
S.L. Davison, R. Bell, S. Donath, J.G. Montalto, S.R. Davis.
Androgen levels in adult females: changes with age, menopause, and oophorectomy.
J Clin Endocrinol Metab, 90 (2005), pp. 3847-3853
[9.]
K.K. Miller, W. Rosner, H. Lee, J. Hier, G. Sesmilo, D. Schoenfeld, et al.
Measurement of free testosterone in normal women and women with androgen deficiency: comparison of methods.
J Clin Endocrinol Metab, 89 (2004), pp. 525-533
[10.]
J.E. Morley, P. Patrick, H.M. Perry 3rd.
Evaluation of assays available to measure free testosterone.
Metabolism, 51 (2002), pp. 554-559
[11.]
W. Reinhardt, D. Patschan, F. Pietruck, T. Philipp, O.E. Janssen, K. Mann, et al.
Free androgen index is superior to total testosterone for short-term assessment of the gonadal axis after renal transplantation.
Horm Res, 64 (2005), pp. 248-252
[12.]
H.G. Burger, M. Igarashi.
Inhibin-definition and nomenclature, including related substances.
J Clin Endocrinol Metab, 66 (1988), pp. 885-886
[13.]
N.P. Groome, P.J. Illingworth, M. O’Brien, R. Pai, J.P. Mather, A.S. Mc-Neilly.
Measurement of dimeric inhibin B thoughout the human menstrual cycle.
J Clin Endocrinol Metab, 81 (1996), pp. 1401-1405
[14.]
A. Sehested, A. Juul, A.M. Andersson, J.H. Petersen, T.K. Jensen, J. Müller, et al.
Serum inhibin A and inhibin B in healthy, prepubertal, pubertal and adolescent girls and adult women: relation to age, stage of puberty, menstrual cycle, follicle-stimulating hormone, luteinizing hormone, and estradiol levels.
J Clin Endocrinol Metab, 85 (2000), pp. 1634-1640
[15.]
A.M. Andersson, J. Toppari, A.M. Haavisto, J.H. Petersen, T. Simell, O. Simell, et al.
Longitudinal reproductive hormone profiles in infants: peak of inhibin B levels in infant boys exceeds levels in adult men.
J Clin Endocrinol Metab, 83 (1998), pp. 675-681
[16.]
M. Chellakooty, I.M. Schmidt, A.M. Haavisto, K.A. Boisen, I.N. Damgaard, C. Mau, et al.
Inhibin A, inhibin B, follicle-stimulating hormone, luteinizing hormone, estradiol, and sex hormone-binding globulin levels in 473 healthy infant girls.
J Clin Endocrinol Metab, 88 (2003), pp. 3515-3520
[17.]
P.M. Crofton, A.E. Evans, N.P. Groome, M.R. Taylor, C.V. Holland, C.J. Kelnar.
Dimeric inhibins in girls from birth to adulthood: relationship with age, pubertal stage, FSH and oestradiol.
Clin Endocrinol (Oxf), 56 (2002), pp. 223-230
[18.]
H. Tinkanen, M. Blauer, P. Laippala, P. Tuohimaa, E. Kujansuu.
Correlation between serum inhibin B and other indicators of ovarian function.
Eur J Obstet Gynecol, 94 (2001), pp. 109-113
[19.]
R.L. Cate, R.J. Mattaliano, C. Hession, R. Tizard, N.M. Farber, A. Cheung, et al.
Isolation of the bovine and human genes for Müllerian inhibiting substance and expression of the human gene in animal cells.
Cell, 45 (1986), pp. 685-698
[20.]
C. Weenen, J.S. Laven, A.R. Von Bergh, M. Cranfield, N.P. Groome, J.A. Visser, et al.
Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment.
Mol Hum Reprod, 10 (2004), pp. 77-83
[21.]
R. Rey, C. Lukas-Croisier, C. Lasala, P. Bedecarras.
AMH/MIS: what we know about the gene, the protein and its regulation.
Mol Cell Endocrinol, 15 (2003), pp. 21-31
[22.]
A.L. Durlinger, M.J. Gruitjers, P. Kramer, B. Karels, T.R. Kumar, M.M. Matzuk, et al.
Anti-Müllerian hormone attenuates the effects of FSH on follicle development in the mouse ovary.
Endocrinology, 142 (2001), pp. 4891-4899
[23.]
M.M. Lee, P.K. Donahoe, T. Hasegawa, B. Silverman, G.B. Crist, S. Best, et al.
Müllerian inhibiting substance in humans: normal levels from infancy to adulthood.
J Clin Endocrinol Metab, 81 (1996), pp. 571-576
[24.]
A. La Marca, A. Volpe.
Anti-Müllerian hormone (AMH) in female reproduction: is measurement of circulating AMH a useful tool?.
Clin Endocrinol, 64 (2006), pp. 603-610
[25.]
J.E. Laven, A.G. Muldres, J.A. Visser, A.P. Themmen, F.H. De Jing, C.J.M. Fauser.
Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age.
J Clin Endocrinol Metab, 89 (2004), pp. 318-323
[26.]
R. Fanchin, L.M. Schonauer, C. Righini, J. Guibourdenche, R. Frydman, J. Taieb.
Serum anti-Müllerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3.
Hum Reprod, 18 (2003), pp. 323-327
[27.]
I.A. Van Rooij, F.J. Broekmans, E.R. Velde, B.C. Fauer, L.F. Bancsi, F.H. Jong, et al.
Serum anti-Müllerian hormone levels: a novel measurement of ovarian reserve.
Hum Reprod, 17 (2002), pp. 3065-3071
[28.]
A. Hazout, P. Bouchard, D.B. Seifer, P. Aussage, A.M. Junca, P. Cohen-Bacrie.
Serum antimüllerian hormone/müllerian inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol.
Fert Steril, 82 (2004), pp. 1323-1329
[29.]
J.C. Achermann.
Development of the reproductive systems.
Brook's Clinical Pediatric Endocrinology, 5th ed, pp. 153-170
[30.]
I. Hernández de la Calle, M. Gussinyé, A. Carrascosa.
Función ovárica.
Tratado de Endocrinología Pediátrica y de la Adolescencia, pp. 945-965
[31.]
K.O. Klein, V. Mericq, J.M. Brown-Dawson, K.A. Larmore, P. Cabezas, A. Cortinez.
Estrogen levels in girls with premature thelarche compared with normal prepubertal girls as determined by an ultrasensitive recombinant cell bioassay.
J Pediatr, 134 (1999), pp. 190-192
[32.]
M.W. Elmlinger, W. Kuhnel, M.B. Ranke.
Reference ranges for serum concentrations of lutropin (LH), follitropin (FSH), estradiol (E2), prolactin, progesterone, sex hormone-binding globulin (SHBG), dehydroepiandrosterone sulfate (DHEAS), cortisol and ferritin in neonates, children and young adults.
Clin Chem Lab Med, 40 (2002), pp. 1151-1160
[33.]
F. Paris, N. Servant, B. Terouanne, P. Balaguer, J.C. Nicolas, C. Sultan.
A new recombinant cell bioassay for ultrasensitive determination of serum estrogenic bioactivity in children.
J Clin Endocrinol Metab, 87 (2002), pp. 791-797
[34.]
K. Bay, A.M. Andersson, N.E. Skakkebaek.
Estradiol levels in prepubertal boys and girls –analytical challenges.
Int J Androl, 27 (2004), pp. 266-273
[35.]
M. Asunción, R.M. Calvo, J.L. San Millán, J. Sancho, S. Ávila, H. Escobar-Morreale.
A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain.
J Clin Endocrinol Metab, 85 (2000), pp. 2434-2438
[36.]
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop.
Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).
Hum Reprod, 19 (2004), pp. 41-47
[37.]
D.A. Ehrmann.
Polycystic ovary syndrome.
New Engl J Med, 352 (2005), pp. 1223-1236
[38.]
L. Ibáñez, N. Potau, I. Francois, F. de Zegher.
Precocious pubarche, hyperinsulinism and ovarian hyperandrogenism in girls: relation to reduced fetal growth.
J Clin Endocrinol Metab, 83 (1998), pp. 3558-3562
[39.]
L. Ibáñez, C. Valls, N. Potau, M.V. Marcos, F. de Zegher.
Polycystic ovary syndrome after precocious pubarche: ontogeny of the low-birthweight effect.
Clin Endocrinol, 55 (2001), pp. 667-672
[40.]
J.C. Marshall.
Obesity in adolescent girls: is excess androgen the real bad actor?.
J Clin Endocrinol Metab, 91 (2006), pp. 393-395
[41.]
R. Pasquali, A. Gambineri, U. Pagotto.
The impact of obesity on reproduction in women with polycystic ovary syndrome.
BJOG, 7 (2006), pp. 1148-1159
[42.]
M.I. New, F. Lorenzen, A.J. Lerner, B. Kohn, S.E. Oberfield, M.S. Pollack, et al.
Genotyping steroid 21-hydroxylase deficiency: hormonal reference data.
J Clin Endocrinol Metab, 56 (1983), pp. 320-325
[43.]
A. Vermeulen, L. Verdonck, J.M. Kaufman.
A critical evaluation of simple methods for the estimation of free testosterone in serum.
J Clin Endocrinol Metab, 84 (1999), pp. 3666-3672
[44.]
R. Stricker, R. Eberhart, M.C. Chevailler, F.A. Quinn, P. Bischof, R. Stricker.
Establishment of detailed reference values for luteinizing hormone, follicle stimulating hormone, estradiol, and progesterone during different phases of the menstrual cycle on the Abbott ARCHITECT((R)) analyzer.
Clin Chem Lab Med, 44 (2006), pp. 883-887
[45.]
L. Ibáñez, F. de Zegher, N. Potau.
Anovulation after precocious pubarche: early markers and time course in adolescence.
J Clin Endocrinol Metab, 84 (1999), pp. 2691-2695
[46.]
L. Ibáñez, N. Potau, A. Ferrer, F. Rodríguez-Hierro, M.V. Marcos, F. de Zegher.
Reduced ovulation rate in adolescent girls born small for gestational age.
J Clin Endocrinol Metab, 87 (2002), pp. 3391-3393
[47.]
P.M. Crofton, A.B. Thomson, A.E. Evans, N.P. Groome, L.E. Bath, C.J. Kelnar, et al.
Is inhibin B a potential marker of gonadotoxicity in prepubertal children treated for cancer?.
Clin Endocrinol (Oxf), 58 (2003), pp. 296-301
[48.]
E.C. Larsen, J. Müller, K. Schmiegelow, C. Rechnitzer, A.N. Andersen.
Reduced ovarian function in long-term survivors of radiation- and chemotherapy-treated childhood cancer.
J Clin Endocrinol Metab, 88 (2003), pp. 5307-5314
[49.]
A. AlQathani, S. Muttukrishna, M. Appasamy, J. Johns, M. Cranfield, J.A. Visser.
Development of a sensitive enzyme immunoassay for anti-Müllerian hormone and its evaluation of potential clinical applications in males and females.
Clin Endocrinol, 63 (2005), pp. 267-273
[50.]
I.A. Van Rooij, I. Tonkelaar, F.J. Broekmans, C.W. Looman, G.J. Scheffer, F.H. De Jong, et al.
Anti-Müllerian hormone is a promising predictor for the occurrence of menopausal transition.
Menopause, 11 (2004), pp. 601-606
[51.]
R. Fanchin, L.M. Schonauer, C. Righini, N. Frydman, R. Frydman, J. Taieb.
Serum anti-Müllerian hormone dynamics during controlled ovarian hyperstimulation.
Hum Reprod, 18 (2003), pp. 328-332
[52.]
A. La Marca, R. Orvieto, S. Giulini, V.M. Jasonni, A. Volpe, V. De Leo.
Müllerian-inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics.
Fertil Steril, 82 (2004), pp. 970-972
[53.]
A.H. Lane, M.M. Lee, A.F. Fuller Jr, D.J. Kehas, P.K. Donahoe, D.T. MacLaughlin.
Diagnostic utility of Müllerian inhibiting substance determination in patients with primary and recurrent granulosa cell tumors.
Gynecol Oncol, 73 (1999), pp. 51-55
[54.]
N. Potau, L. Ibáñez, M. Sentís, A. Carrascosa.
Sexual dimorphism in the maturation of the pituitary-gonadal axis, assessed by GnRH agonist challenge.
Eur J Endocrinol, 141 (1999), pp. 27-34
[55.]
L. Ibáñez, N. Potau, M. Zampolli, N. Prat, M. Gussinyé, P. Saenger, et al.
Source localization of androgen excess in adolescent girls.
J Clin Endocrinol Metab, 79 (1994), pp. 1778-1784
[56.]
L. Ibáñez, N. Potau, M. Zampolli, R. Virdis, M. Gussinyé, A. Carrascosa, et al.
Use of leuprolide acetate response patterns in the early diagnosis of pubertal disorders: Comparison with the gonadotropin-releasing hormone test.
J Clin Endocrinol Metab, 78 (1994), pp. 30-35
[57.]
P. Saenger, K. Albertsson-Wikland, G.S. Conway, M. Davenport, C.H. Gravholt, R. Hintz, et al.
Recommendations for the diagnosis and management of Turner symdrome.
J Clin Endocrinol Metab, 86 (2001), pp. 3061-3069
[58.]
R.G. Rosenfeld.
A Shox to the system [editorial].
J Clin Endocrinol Metab, 86 (2001), pp. 5672-5673
[59.]
F. Álvarez-Nava, M. Soto, M.A. Sánchez, E. Fernández, R. Lanes.
Molecular analysis of Turner syndrome.
J Pediatr, 142 (2003), pp. 336-340
[60.]
H. Meng, K. Hager, S.A. Rivkees, J.R. Gruen.
Detection of Turner syndrome using high-throughput quantitative genotyping.
J Clin Endocrinol Metab, 90 (2005), pp. 3419-3422
[61.]
N. Massin, C. Czernichow, E. Thibaud, F. Kuttenn, M. Polak, P. Touraine.
Idiopathic premature ovarian failure in 63 young women.
Horm Res, 65 (2006), pp. 89-95
[62.]
M.F. Portnoi, A. Aboura, G. Tachdjian, P. Bouchard, D. Dewailly, N. Bourcigaux, et al.
Molecular cytogenetic studies of Xq critical regions in premature ovarian failure.
Hum Reprod, 21 (2006), pp. 2329-2334
[63.]
R.L. Prueitt, H. Chen, R.I. Barnes, A.R. Zinn.
Most X; autosome translocations associated with premature ovarian failure do not interrupt X-linked genes.
Cytogenet Genome Res, 97 (2002), pp. 32-38
Copyright © 2007. Sociedad Española de Endocrinología y Nutrición
